ArticleImmunotherapy2025
Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events.
Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer.Drugs - real world outcomes · 2026Article
- Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study).Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsImmune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting approximately half of ICI-treated patients. irAEs may be severe and result in hospitalization. This study examined the risk factors and outcomes of irAE-related hospitalization.
methodsWe conducted a retrospective study including 202 metastatic cancer patients treated with ICIs at Kuopio University Hospital, Finland, in 2015-2022.
resultsIrAEs occurred in 57.4% of the patients. About 26.0% of them required inpatient treatment. Hospitalization was associated with severe (grades III - IV) toxicities and need for systemic corticosteroids. Median overall survival (mOS) for hospitalized patients was 12.9 months and for outpatients with irAEs 26.9 months (
conclusionsIrAE-related hospitalization deteriorated the survival of ICI-treated patients, likely due to decreased biological efficacy of ICIs resulting from short therapy periods and strong immunosuppression by glucocorticoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.